Zentalis Pharmaceuticals
Zentalis Pharmaceuticals' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$125 million. It paid out $10 million in dividends and buybacks. The diluted share count rose 1.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Zentalis Pharmaceuticals lost money in fiscal 2025: a net loss of $137 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 60 | 43 | 483 | 352 | 246 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 8.0x | 8.0x | 7.2x | 7.3x | 6.9x |
| Quick ratio | 8.0x | 8.0x | 7.2x | 7.3x | 6.9x |
Cash flow
Projections
Project Zentalis Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $22.9 million of Zentalis Pharmaceuticals shares on the open market, and 4 insiders sold $10.1 million, $105,418 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | William Thurman Walters10% owner | Bought | 4,335,000 | $3.50 | $15.2 million | Form 4 |
| Feb 10, 2026 | Vincent VultaggioPAO and PFO | Sold plan | 6,894 | $2.42 | $16,683 | Form 4 |
| Feb 9, 2026 | Vincent VultaggioPAO and PFO | Sold plan | 3,379 | $2.39 | $8,076 | Form 4 |
| Feb 9, 2026 | Julia Marie EastlandCEO & President, Director | Sold | 889 | $2.39 | $2,125 | Form 4 |
| Feb 9, 2026 | Ingmar BrunsChief Medical Officer | Sold | 335 | $2.39 | $801 | Form 4 |
| Feb 6, 2026 | Vincent VultaggioPAO and PFO | Sold plan | 29,951 | $2.43 | $72,781 | Form 4 |
| Feb 6, 2026 | Julia Marie EastlandCEO & President, Director | Sold | 7,866 | $2.43 | $19,114 | Form 4 |
| Feb 6, 2026 | Ingmar BrunsChief Medical Officer | Sold | 2,962 | $2.43 | $7,198 | Form 4 |
| Feb 3, 2026 | Vincent VultaggioPAO and PFO | Sold plan | 556 | $2.52 | $1,401 | Form 4 |
| Feb 2, 2026 | Vincent VultaggioPAO and PFO | Sold plan | 2,540 | $2.55 | $6,477 | Form 4 |
| Dec 31, 2025 | William Thurman Walters10% owner | Bought | 6,459,973 | $1.20 | $7.8 million | Form 4 |
| Dec 15, 2025 | David E. Goel10% owner | Sold | 7,500,000 | $1.33 | $10.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 0.20 | −2.09 | −8.96 |
| Accruals ratio | −15.5% | 1.0% | −3.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Zentalis Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals | FY25 | −100.0% | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | 0 | 0 | 67 | 0 |
| Revenue growth | — | — | — | — | — | — | −100.0% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 38 | 85 | 176 | 173 | 190 | 168 | 107 |
| Operating income | −47 | −119 | −216 | −227 | −300 | −191 | −153 |
| Net income | −46 | −118 | −159 | −237 | −292 | −166 | −137 |
| Diluted EPS (US$) | −8.16 | −4.19 | −3.72 | −4.48 | −4.47 | −2.33 | −1.91 |
| Diluted shares (millions) | 6 | 28 | 43 | 53 | 65 | 71 | 72 |
| Cash flow | |||||||
| Cash from operations | −39 | −87 | −154 | −164 | −208 | −171 | −125 |
| Capital expenditure | 0 | 1 | 6 | 2 | 1 | 0 | 0 |
| Free cash flow | −39 | −88 | −160 | −166 | −208 | −171 | −125 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 23 | 36 | 47 | 55 | 67 | 21 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 67 | 55 | 60 | 43 | 483 | 352 | 246 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 88 | 366 | 454 | 539 | 552 | 430 | 289 |
| Total liabilities | 19 | 32 | 90 | 105 | 114 | 93 | 73 |
| Shareholders' equity | −73 | 333 | 364 | 434 | 437 | 337 | 216 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −283.6% | — |
| Net margin | — | — | — | — | — | −246.0% | — |
| Free cash flow margin | — | — | — | — | — | −253.7% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −90.6% | −45.5% | −59.3% | −67.1% | −42.8% | −49.5% |
| Return on assets | — | −52.0% | −38.7% | −47.7% | −53.6% | −33.8% | −38.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |